Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Recruiting · NCT06517719 · Observational (researchers observe without assigning treatment) · Lead sponsor: Novartis Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
lutetium (177Lu) vipivotide tetraxetan
What this trial is about
The purpose of this study is to describe routine clinical practice with lutetium (177Lu) vipivotide tetraxetan on Health related quality of life (HRQoL) at baseline, on treatment, and post progression.
Who can take part
Age range
18 Years to 99 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- All patients must meet the following inclusion criteria during the identification period:
- Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
- ≥ 18 years old at the time of enrollment
- Written informed consent must be obtained prior to any data collection
- Willing to participate in Quality of Life post treatment date collection for 1 year
Exclusion criteria
- Patients must not meet the following exclusion criterion during the identification period:
- \- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan
Where it is running
38 locations listed.
- Novartis Investigative Site - Aachen, Germany
- Novartis Investigative Site - Augsburg, Germany
- Novartis Investigative Site - Berlin, Germany
- Novartis Investigative Site - Berlin, Germany
- Novartis Investigative Site - Berlin, Germany
- Novartis Investigative Site - Bielefeld, Germany
- Novartis Investigative Site - Bonn, Germany
- Novartis Investigative Site - Braunschweig, Germany
- Novartis Investigative Site - Chemnitz, Germany
- Novartis Investigative Site - Dortmund, Germany
- Novartis Investigative Site - Dortmund, Germany
- Novartis Investigative Site - Erfurt, Germany
- Novartis Investigative Site - Erlangen, Germany
- Novartis Investigative Site - Essen, Germany
- Novartis Investigative Site - Fulda, Germany
- Novartis Investigative Site - Herford, Germany
- Novartis Investigative Site - Homburg, Germany
- Novartis Investigative Site - Magdeburg, Germany
- Novartis Investigative Site - Mainz, Germany
- Novartis Investigative Site - Nuremberg, Germany
- Novartis Investigative Site - Rostock, Germany
- Novartis Investigative Site - Trier, Germany
- Novartis Investigative Site - Tübingen, Germany
- Novartis Investigative Site - Ulm, Germany
- Novartis Investigative Site - Konstanz, Baden-Wurttemberg, Germany
- Novartis Investigative Site - Stuttgart, Baden-Wurttemberg, Germany
- Novartis Investigative Site - Munich, Bavaria, Germany
- Novartis Investigative Site - Regensburg, Bavaria, Germany
- Novartis Investigative Site - Würzburg, Bavaria, Germany
- Novartis Investigative Site - Cottbus, Brandenburg, Germany
- Novartis Investigative Site - Frankfurt (Oder), Brandenburg, Germany
- Novartis Investigative Site - Ludwigshafen, Germany, Germany
- Novartis Investigative Site - Marburg, Hesse, Germany
- Novartis Investigative Site - Cologne, North Rhine-Westphalia, Germany
- Novartis Investigative Site - Dresden, Saxony, Germany
- Novartis Investigative Site - Leipzig, Saxony, Germany
- Novartis Investigative Site - Halle, Saxony-Anhalt, Germany
- Novartis Investigative Site - Jena, Thuringia, Germany